Alembic Pharmaceuticals Share Price Rises 1.14 Percent After USFDA Final Approval for Prucalopride Tablets

Alembic Pharmaceuticals share price moved higher on 28 July 2026 after the company secured a fresh regulatory approval in the United States. The stock was quoting at Rs 823.70, up Rs 9.25 or 1.14 percent, as investors responded positively to the company's expanding portfolio of approved generic products.

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application Prucalopride Tablets, 1 mg and 2 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product, Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc. Prucalopride tablets are a serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults.

Click Here – Get Free Investment Predictions

Alembic Pharmaceuticals Share Price Today: Key Trading Levels

Alembic Pharmaceuticals share price touched an intraday high of Rs 826.85 and an intraday low of Rs 812.90 during Tuesday's session. The stock was trading with volumes of 4,466 shares, compared to its five day average of 3,504 shares, an increase of 27.46 percent, indicating higher than usual participation around the approval news.

Metric	Value
Company	Alembic Pharmaceuticals
CMP	Rs 823.70
Change	Rs +9.25 (+1.14 percent)
Intraday High	Rs 826.85
Intraday Low	Rs 812.90
Volume	4,466 shares
5 Day Average Volume	3,504 shares

Check Live Stock Screener for More Pharma Sector Picks

What the Prucalopride Tablets Approval Means

Prucalopride tablets work as a serotonin-4 receptor agonist and are used to treat chronic idiopathic constipation in adults, a condition affecting a meaningful patient population in the United States. The reference product, Motegrity Tablets from Takeda Pharmaceuticals USA, gives Alembic Pharmaceuticals a clear branded benchmark to compete against as it rolls out its generic version in the American market, one of the largest and most closely watched pharmaceutical markets in the world.

Alembic Pharmaceuticals share price reaction reflects the market's generally favourable view of USFDA approvals, since final approval clears the last major regulatory hurdle before a company can begin commercial shipments of the approved generic product in the United States, one of the largest and most closely watched pharmaceutical markets globally. Such approvals also add to a company's long-term revenue visibility once commercial launch begins.

Alembic Pharmaceuticals' US Generics Pipeline

Alembic Pharmaceuticals has built a sizeable portfolio of ANDA approvals over the years across therapeutic areas including gastroenterology, cardiovascular, and anti-infective segments, with the US generics business remaining a key growth driver for the company alongside its domestic formulations and active pharmaceutical ingredients operations. The company has consistently added to its filed and approved ANDA count over recent years as part of a broader strategy to diversify its product mix in the regulated US market and reduce dependence on any single therapeutic category.

Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals share price movements live and get USFDA approval alerts.

Conclusion

Alembic Pharmaceuticals share price rose 1.14 percent to Rs 823.70 on 28 July 2026 after the company received final USFDA approval for its Prucalopride Tablets ANDA, therapeutically equivalent to Takeda's Motegrity Tablets. The approval adds one more product to Alembic Pharmaceuticals' growing list of US generic approvals across multiple therapeutic categories. Investors tracking Alembic Pharmaceuticals share price should watch for the product's commercial launch timeline and consult a SEBI-registered investment advisor before making any investment decision.

FAQs

Why did Alembic Pharmaceuticals share price rise on 28 July 2026?

Ans. Alembic Pharmaceuticals share price rose 1.14 percent to Rs 823.70 after the company received final USFDA approval for its Prucalopride Tablets ANDA in 1 mg and 2 mg strengths.

What is Prucalopride used to treat?

Ans. Prucalopride tablets are a serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults.

What is the reference drug for Alembic Pharmaceuticals' approved Prucalopride ANDA?

Ans. The approved ANDA is therapeutically equivalent to the reference listed drug product, Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals USA Inc.

What was the intraday range for Alembic Pharmaceuticals share price today?

Ans. Alembic Pharmaceuticals share price touched an intraday high of Rs 826.85 and an intraday low of Rs 812.90 during the session on 28 July 2026.

What was the trading volume for Alembic Pharmaceuticals share price today?

Ans. Alembic Pharmaceuticals share price traded with volumes of 4,466 shares, compared to its five day average of 3,504 shares, an increase of 27.46 percent.

Is Alembic Pharmaceuticals share price a good buy after the USFDA approval?

Ans. Investors should evaluate Alembic Pharmaceuticals share price alongside the company's broader US generics pipeline, valuation, and sector trends, and consult a SEBI-registered investment advisor before making any buy, hold, or sell decisions.

What regulatory body approved Alembic Pharmaceuticals' Prucalopride Tablets?

Ans. The US Food and Drug Administration granted final approval for Alembic Pharmaceuticals' Abbreviated New Drug Application for Prucalopride Tablets, 1 mg and 2 mg.